Statistics

Total Visits

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER241

Select a period of time:

Number of views in the range

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER221

Views

Views
January 20250
February 20253
March 202516
April 20252
May 20250
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United States4
Spain1
 

Top cities views

Views
Buffalo2
Council Bluffs1
Pasadena1